Łagocka Ryta, Dziedziejko Violetta, Kłos Patrycja, Pawlik Andrzej
Department of Conservative Dentistry and Endodontics, Pomeranian Medical University, 70-204 Szczecin, Poland.
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-204 Szczecin, Poland.
J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273.
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along with its effectiveness in treating other human RNA infections.
法匹拉韦（FPV）是一种新型抗病毒药物，作为RNA依赖性RNA聚合酶（RdRp）的竞争性抑制剂，可阻止病毒转录和复制。2014年，FPV在日本获批用于治疗对标准抗病毒疗法无反应的流感。FPV还被用于治疗埃博拉病毒病（EVD）和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。在本综述中，我们讨论了FPV的作用机制、药代动力学参数、毒性和不良反应，以及评估FPV在治疗流感病毒（IV）感染、EVD和SARS-CoV-2感染中的应用的临床研究，及其在治疗其他人类RNA感染中的有效性。
